Brief Report: Severe Pneumonitis After Combined Thoracic Radiotherapy and Osimertinib
Introduction: Osimertinib is an effective treatment for metastatic NSCLC. Occasionally, thoracic radiation therapy (TRT) is delivered to patients receiving osimertinib to treat residual or progressing pulmonary tumors. Anecdotal reports suggest that the delivery of TRT in combination with osimertini...
Main Authors: | Clayton P. Smith, MD, Michael Xiang, MD, PhD, Stephanie M. Yoon, MD, Alan Lee, MD, Dan Ruan, PhD, Jonathan W. Goldman, MD, Amy L. Cummings, MD, Aaron Lisberg, MD, Edward B. Garon, MD, MS, Drew Moghanaki, MD, MPH |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-03-01
|
Series: | JTO Clinical and Research Reports |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2666364323000073 |
Similar Items
-
Pneumonitis in Patients Receiving Thoracic Radiotherapy and Osimertinib: A Multi-Institutional Study
by: Leou Ismael Banla, MD, PhD, et al.
Published: (2023-10-01) -
Adjuvant Osimertinib in Patients With Stage IB to IIIA EGFR Mutation-Positive NSCLC After Complete Tumor Resection: ADAURA China Subgroup Analysis
by: Jie Wang, MD, PhD, et al.
Published: (2024-02-01) -
Trastuzumab-Emtansine and Osimertinib Combination Therapy to Target HER2 Bypass Track Resistance in EGFR Mutation-Positive NSCLC
by: M. Jebbink, MD, et al.
Published: (2023-04-01) -
Life-Threatening Myositis in a Patient With EGFR-Mutated NSCLC on Osimertinib: Case Report
by: Fionnuala Crowley, MB BCh BAO, et al.
Published: (2022-01-01) -
Successful osimertinib rechallenge without concomitant corticosteroids after osimertinib-induced pneumonitis
by: Taisuke Ito, et al.
Published: (2024-01-01)